	US 12,202,834 B2
	Solid state forms of oclacitinib maleate
Bin Li, Zhejiang (CN); Analia Ivanna Chamorro Orue, Bochum (DE); and Anna Katharina Mellor, Bristol (GB)
Assigned to VationPharma B.V., Panningen (NL)
Appl. No. 17/426,931
Filed by VationPharma B.V., Panningen (NL)
PCT Filed Jan. 29, 2020, PCT No. PCT/NL2020/050045 § 371(c)(1), (2) Date Jul. 29, 2021, PCT Pub. No. WO2020/159362, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 2022471 (NL), filed on Jan. 29, 2019.
Prior Publication US 2022/0098206 A1, Mar. 31, 2022
Int. Cl. C07D 487/04 (2006.01)

CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)]

15 Claims

1. A crystalline monohydrate form of oclacitinib maleate characterized by having an x-ray powder diffraction pattern comprising a characteristic peak at about 5.93±0.2° 2θ.